Why the study?
Do liposome-based drug-delivery systems reduce cardiotoxicity compared to conventional doxorubicin in patients receiving chemotherapy?
Do liposome-based drug-delivery systems reduce cardiotoxicity compared to conventional doxorubicin in patients receiving chemotherapy?
Liposomal formulations of doxorubicin provide a strategy to reduce the cumulative and irreversible cardiotoxicity associated with conventional doxorubicin therapy.
Answers are grounded in this paper and cite their sources.
Supports consideration of pegylated liposomal doxorubicin to limit cardiotoxicity; leaves open need for prospective randomized confirmation.
Anthracyclines are powerful anticancer agents and among the most important tools in the chemotherapy armamentarium of medical oncologists. They are approved for use in the treatment of a broad variety of solid and hematologic neoplasms. However, the usefulness of these agents, particularly doxorubicin, the most widely used anthracycline, is limited by considerable toxicity, especially damage to the cardiac muscle, which is cumulative and mostly irreversible, restricting extended use of this drug. In the last 30 years, extensive research with a variety of drug-delivery systems has attempted to overcome this limitation, with clinical success mostly confined to liposome formulations. Liposomal doxorubicin, and particularly pegylated liposomal doxorubicin, has shown significant pharmacologic advantages and an added clinical value over doxorubicin. Here, we review the mechanisms of action and toxicity of doxorubicin, and ways to reduce toxicity, with a focus on liposome-based drug-delivery systems.
No takes yet. Share an insight, caveat, or question.
Tahover et al. (2014) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: